SCHEMBL6656532

SCHEMBL6656532

CCC1CC(=O)N(Cc2cccc(NC(=O)c3ccco3)c2)N=C1c1ccc(OC)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.49
MAPK1 P28482 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
PDE4D Q08499 8/20 0.46
PDE4A P27815 7/20 0.46
PDE4B Q07343 7/20 0.46
PDE4C Q08493 7/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
MAPT P10636 3/20 0.45
GAA P10253 2/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MET P08581 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6662496 0.93 TSHR (0.53) TSHRMAPK1NPSR1CYP1A2CYP3A4
SCHEMBL6657125 0.93 PDE4D (0.50) TSHRMAPK1NPSR1CYP1A2CYP3A4
SCHEMBL6660992 0.91 PDE4D (0.45) TSHRMAPK1NPSR1CYP1A2CYP3A4
SCHEMBL6681507 0.89 PDE4D (0.45) PDE4DPDE4APDE4BPDE4CMAPT
SCHEMBL6659625 0.88 PDE4D (0.51) PDE4DPDE4APDE4BPDE4CMAPT
SCHEMBL6657674 0.88 PDE4D (0.49) TSHRPDE4DPDE4APDE4BPDE4C
SCHEMBL6662641 0.88 PDE4D (0.49) PDE4DPDE4APDE4BPDE4CMAPT
SCHEMBL6658006 0.88 SMN1; SMN2 (0.50) TSHRMAPK1NPSR1CYP1A2CYP3A4
SCHEMBL6657183 0.88 SMN1; SMN2 (0.50) TSHRMAPK1NPSR1CYP1A2CYP3A4
SCHEMBL6658421 0.88 PDE4D (0.46) PDE4DPDE4APDE4BPDE4CMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B TSHR 3270/4885MAPK1 1267/4885NPSR1 3604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.